The company have recently advised that they will not be pursuing a licensing application for pembrolizumab from the European Medicines Authority for this indication at this time.
| Status | Suspended |
| Decision | Selected |
| Process | STA pre-2018 |
| ID number | 1139 |
Project Team
| Project lead | Stephanie Yates |
Email enquiries
- If you have any queries please email TACommC@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 August 2017 | Suspended. The company have recently advised that they will not be pursuing a licensing application for pembrolizumab from the European Medicines Authority for this indication at this time. |
| 03 August 2017 | As you will be aware, the Department of Health has asked NICE to carry out a Single Technology Appraisal of pembrolizumab in combination with pomalidomide and dexamethasone for treated multiple myeloma. However, the company have recently advised that they will not be pursuing a licensing application for pembrolizumab from the European Medicines Authority for this indication at this time. This follows on from information provided that one of the pivotal phase III trials relevant to this proposed indication had been put on full clinical hold. Please refer to the following link for further information http://www.mrknewsroom.com/news-release/prescription-medicine-news/merck-provides-further-update-three-multiple-myeloma-studies Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 29 March 2017 - 28 April 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 01 March 2017 | Referral |
| 05 December 2016 | In progress. Topic Referred |
For further information on our processes and methods, please see our CHTE processes and methods manual